CMPS Insider Trading
Insider Ownership Percentage: 4.25%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $16,376,463.02
COMPASS Pathways Insider Trading History Chart
This chart shows the insider buying and selling history at COMPASS Pathways by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
COMPASS Pathways Share Price & Price History
Current Price: $2.83
Price Change: ▼ Price Decrease of -0.26 (-8.41%)
As of 04/3/2025 05:00 PM ET
COMPASS Pathways Insider Trading History
COMPASS Pathways Institutional Trading History
Data available starting January 2016
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Read More on COMPASS Pathways
Volume
779,244 shs
Average Volume
755,640 shs
Market Capitalization
$262.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.29
Who are the company insiders with the largest holdings of COMPASS Pathways?
COMPASS Pathways' top insider shareholders include:
- Life Sciences NV Atai (Major Shareholder)
- Ekaterina Malievskaia (Director)
- George Jay Goldsmith (Director)
- Ekaterina Malievskaia (Major Shareholder)
- George Jay Goldsmith (Major Shareholder)
Learn More about top insider investors at COMPASS Pathways.